YDES YDES
Company Profile ↓Company Overview
YDES (YDES) is a publicly traded company listed on with a market capitalization of $279.62M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 30.6% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $596.82K (+16.9% YoY); net profit $-8.31M.
- Trailing 12 Months Year-on-year growth — revenue +16.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 30.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 30.56% |
| 1 Year: | 16.94% |
Stock Price Performance
| 1 Year: | -78.53% |
| 6 Months: | -49.20% |
| 3 Months: | +16.52% |
| 1 Month: | +32.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)53.95 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 30.6% over 5 years.
CONS
- Trading 81.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 350.13K | 510.36K | 596.82K |
| Cost of Revenue | 196.69K | 355.00K | 429.41K |
| Gross Profit | 153.44K | 155.36K | 167.41K |
| Operating Expenses | 160.56K | 1.62M | 5.44M |
| Operating Income | -7.12K | -1.46M | -5.27M |
| EBITDA | 22.25K | -1.28M | -8.10M |
| Interest Expense | 2.14K | 772 | 0 |
| Pretax Income | 17.65K | -1.39M | -8.31M |
| Tax Provision | 4.09K | 25.08K | -1.53K |
| Net Income | 13.56K | -1.41M | -8.31M |
| Diluted EPS | 0.00 | -0.02 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 321.21K | 6.86M | 13.78M |
| Current Assets | 271.72K | 3.47M | 9.67M |
| Cash & Equivalents | 87.10K | 3.13M | 6.01M |
| Inventory | 69.40K | 37.34K | 1.88M |
| Receivables | 98.17K | 86.58K | 167.48K |
| Total Liabilities | 298.22K | 273.98K | 16.64M |
| Current Liabilities | 298.22K | 263.06K | 1.64M |
| Long Term Debt | - | - | - |
| Total Debt | 47.58K | 22.27K | 6.76K |
| Total Equity | 22.99K | 6.59M | -2.86M |
| Shares Outstanding | 70.10M | 70.10M | 70.79M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -55.66K | -1.22M | -6.60M |
| Investing Cash Flow | -290 | -2.90M | -1.44M |
| Financing Cash Flow | 113.89K | 7.11M | 10.87M |
| Capital Expenditure | -290 | -2.91M | -1.44M |
| Free Cash Flow | -55.95K | -4.13M | -8.04M |
| Net Change in Cash | 57.94K | 2.99M | 2.83M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | 43.8% | 30.4% | 28.1% |
| Operating Margin % | -2.0% | -286.5% | -882.7% |
| Net Margin % | 3.9% | -276.6% | -1,392.6% |
| ROE % | 59.0% | -21.4% | 291.0% |
| ROCE % | -30.9% | -22.2% | -43.4% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for YDES
YD Bio Limited Reports Full Year 2025 Financial Results
TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announce…
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute
Two chrono-nutrition formulations — a daytime lipid-soluble “Golden Triangle” formula and a nighttime zinc-plus-calcium formula — were developed in collaboration with the Taiwan CDHA and FHI. The Company intends to expand this approach by e…
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research
Published in Bioengineering, a collaborative study with Taipei Medical University researchers identifies key molecular candidates to help guide the development of regenerative therapies for corneal disease. TAIPEI, Taiwan, Aug. 04, 2026 (GL…
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada
The six-month pilot is designed to evaluate the potential scalability of bringing physician-ordered, blood-based OkaiDx laboratory-developed tests to patients in Canada Taipei, Taiwan, July 28, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD B…
YD Bio and EG BioMed Conclude Successful Exhibition at BIO Asia-Taiwan 2026, Highlighting Innovations in Ophthalmology, Oncology Diagnostics, and Clinical Services
Taipei, Taiwan, July 23, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced…
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026
TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced…
YDES — Frequently Asked Questions
What is the current share price of YDES?
As of 2026-09-16 18:39 PDT, YDES trades at $3.95 on NASDAQ/NYSE. Its 52-week range is $1.90 to $21.06.
What is the market capitalisation of YDES?
YDES has a market capitalisation of $279.62M on NASDAQ/NYSE.
What is the P/E ratio of YDES?
YDES trades at a trailing price-to-earnings (P/E) ratio of -196.15. Its price-to-book (P/B) ratio is -98.01.
Is YDES a good stock to buy?
This page provides a data-driven analysis of YDES, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.